In a follow-up study by Newcomb et al., the addition of PCA3 to clinical parameters (serum PSA, core PCa ratio, and prostate size) only provided a slight improvement of AUC (0.753 versus 0.743) for predicting risk reclassification at the first surveillance biopsy (n = 552) [22]. This evidence concerns the gene PCA3 and posterior cortical atrophy.